You searched for "lasers"
The PMFA Journal - October/November 2018 issue available
FEATURES IN THIS ISSUE: A practical guide to the most commonly used dressings in wound care by Sotirios Foutsizoglou. / Raising the bar for safer cosmetic surgery in the UK - part 2 by James D Frame. AND SO MUCH MORE...The PMFA Journal - December/January 2019 issue available
FEATURES IN THIS ISSUE: Life after medicine by Andrew Burd. / The creation of PlayDoh® models as an educational tool for teaching anatomy of the eyelid by Maria De Bono Agius, Roth M Manners, Fiona R Jazayeri, Christina V Miller and Sally M Webber. AND MUCH MORE...The PMFA Journal - April/May 2019 issue available
FEATURES IN THIS ISSUE: Genioplasty by Natasha Berridge and Paul Johnson. / Immediate versus delayed post mastectomy breast reconstruction by Diaa Othman, Adil Khan and Mumahhad Riaz. / Laser tattoo removal by Dana Alessa and Eric F Bernstein. AND MUCH MORE...
Multimodal Retinal Imaging
Understanding of rapidly advancing retinal imaging techniques is important as they have changed the management of retinal conditions considerably. Interpretation of these tests is a vital skill in the armamentarium of every practising ophthalmologist. The book is directed at general...
ROP ocular outcomes after Bevacizumab treatment
The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of...
ROP incidence and treatment profile over time
The primary aims of this study were to report the incidence of severe ROP and its treatment in infants <27 and 30 weeks gestational age. Secondary aims were to compare this data with three previously reported cohorts: 2003-2005; 200/2550 with...
Aflibercept, bevacizumab or ranibizumab for DMO
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
Update on primary angle closure glaucoma
This review article considers primary angle-closure glaucoma which is responsible for half of glaucoma-related blindness worldwide. Angle closure is characterised by appositional contact between the iris and trabecular meshwork. It tends to develop in eyes with shallow anterior chambers, anteriorly...
Aflibercept for the treatment of neovascular glaucoma
The aim of this study was to investigate initial results regarding the treatment of neovascular glaucoma (NVG) with intravitreal aflibercept. NVG is classified into stages 0-3. In stages 1 and 2, abnormal vessel proliferation is seen with or without elevated...
Simple approach to prevent capsule tear-out during capsulorhexis creation in hyper mature cataracts
Puncturing the anterior capsule in the anterior chamber so that the pressure falls below intracapsular tension causes the rhexis to extend out to the equator. If this develops into a tear that wraps around the entire lens it is called...
Sustained elevation of extracellular ATP in chronic glaucoma
Although adenosine 5′-triphosphate (ATP) release from retinal neurons and astrocytes has been demonstrated in short-term increases in intraocular pressure (IOP); such as in aqueous humor of humans with primary acute angle closure glaucoma, the response in chronic IOP elevation was...
